Brainsway: HC Wainwright Raises PT to $17, Maintains Buy Rating

Brainsway: HC Wainwright Raises PT to $17, Maintains Buy Rating

Brainsway Ltd. (NASDAQ: BNSW) has received a positive update from HC Wainwright, with the investment research firm raising its price target for the company's stock to $17 from $14. The analyst maintains a "Buy" rating, citing the company's strong financial performance and promising pipeline. The move comes after Brainsway reported record quarterly revenue and installed base growth in its second quarter earnings report.

During the quarter ended June 30, 2025, Brainsway delivered record revenue of $12.6 million, up 26% year-over-year (YoY), and shipped 88 Deep TMS systems, a 35% increase from the same period last year [1]. The company's total installed base now stands at 1,522 systems. Multi-year lease agreements now represent 70% of customer engagements, contributing to a $62 million backlog of remaining performance obligations and providing clear revenue visibility [1].

HC Wainwright praised Brainsway's recurring revenue model and disciplined cost management, which have driven steady growth and strong gross margins. The analyst also highlighted the company's clinical advancements, such as an accelerated Deep TMS protocol submitted to the FDA, which could boost patient adoption. Additionally, Brainsway's strategic investments in mental health providers, including a $5 million minority investment in Stella MSO, were cited as a positive development [1].

The analyst maintains that Brainsway's strong fundamentals and growth prospects justify its "Buy" rating and the new price target of $17. Investors should continue to monitor the company's progress in expanding its Deep TMS platform and integrating it into global healthcare systems.

References:
[1] https://www.marketbeat.com/earnings/reports/2025-8-13-brainsway-ltd-stock/